David M. Heery

University Park
Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.

Journal: Molecular oncology

Published: May 08, 2025

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth.

Thyroid hormone receptor beta signaling is a targetable driver of prostate cancer growth.

Journal: Molecular cancer

Published: April 14, 2025

Sex-specific attenuation of constant light-induced memory impairment and Clock gene expression in brain in hepatic Npas2 knockout mice.

Sex-specific attenuation of constant light-induced memory impairment and Clock gene expression in brain in hepatic Npas2 knockout mice.

Journal: Scientific reports

Published: August 21, 2024

Modern Approaches to Mouse Genome Editing Using the CRISPR-Cas Toolbox and Their Applications in Functional Genomics and Translational Research.

Modern Approaches to Mouse Genome Editing Using the CRISPR-Cas Toolbox and Their Applications in Functional Genomics and Translational Research.

Journal: Advances in experimental medicine and biology

Published: July 24, 2023

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.

Journal: Molecular cancer

Published: March 23, 2023

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Apoptotic cell death in disease-Current understanding of the NCCD 2023.

Journal: Cell death and differentiation

Published: January 30, 2023

The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.

The KDM5B and KDM1A lysine demethylases cooperate in regulating androgen receptor expression and signalling in prostate cancer.

Journal: Frontiers in cell and developmental biology

Published: December 05, 2022

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer.

PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer.

Journal: Frontiers in cell and developmental biology

Published: October 20, 2021

FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer.

FcγRIIIa receptor interacts with androgen receptor and PIP5K1α to promote growth and metastasis of prostate cancer.

Journal: Molecular oncology

Published: July 07, 2021

Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.

Thyroid and androgen receptor signaling are antagonized by μ-Crystallin in prostate cancer.

Journal: International journal of cancer

Published: July 23, 2020

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Journal: Breast cancer research : BCR

Published: January 21, 2020

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy.

Journal: Oncology and therapy

Published: November 18, 2019

Showing 1-12 of 35

Last Updated: 09/26/2026